You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back


In these pages you can find out about our Urology portfolio, find information on BPH and download useful patient resources.

Drug-disease modelling: BPH Webinar 25th September 2019

ELITE Webcast


The impact of early vs delayed initiation of combination therapy for BPH medical management

Watch expert discussion on clinical management now.

What is BPH?

Benign Prostatic Hyperplasia (BPH) relates to the non-cancerous growth of the prostate.
As the prostate enlarges and BPH progresses, urinary frequency becomes an increasing issue and men may need to wake more often during the night. This degree of nocturia is not a natural part of aging, and seriously disrupts sleep, reducing daytime energy and negatively affecting daily activities and general well being.

BPH can be progressive and, without treatment, the prostate continues to grow and symptoms become more severe. In some cases, this results in complete blockage of the urethra and a sudden inability to pass urine. This condition, known as acute urinary retention (AUR), is a medical emergency that is often unexpected and painful, and requires immediate catheterisation.2 3

Benign Prostate Hyperplasia (BPH) Patient Information

Download explanatory leaflet for patients including: What is BPH? , What is the prostate? BPH symptoms, FAQ’s and more.

Download now

                             Order hard copies

Facts about BPH Inphographic

Download infographic for patients with quick facts about BPH.

Download now

                             Order hard copies

Symptoms of BPH

Clinically, patients with lower urinary tract symptoms (LUTS) due to BPH present with two types of symptoms:


  • Weak stream 
  • Hesitancy 
  • Intermittency 
  • Straining


  • Frequency 
  • Nocturia 
  • Urgency 
  • Urge incontinence

While voiding symptoms are more common, storage symptoms are more bothersome and interfere more with daily activities. Thus they have a considerable effect on quality of life and are the main reason that patients seek medical advice.4

Diagnosis of BPH

BPH is usually diagnosed on the basis of the patient’s medical history, a physical examination (including digital rectal examination [DRE]), an evaluation of LUTS severity, and the measurement of serum PSA levels.5

PSA and DRE should be investigated in accordance with the NCCP Prostate Cancer Referral Guideline.

The severity of LUTS associated with BPH is most commonly evaluated with a self administered questionnaire, such as the International Prostate Symptom Score

Progressive nature of BPH

The prostate grows slowly over time. BPH can be progressive in nature and can lead to worsening symptoms, increased adverse effect on quality of life, development of complications such as acute urinary retention (AUR) and urinary tract infections (UTIs) and need for surgical intervention.

Clinical markers for BPH progression include:5 6

  • Enlarged prostate size (>30cm3)
  • PSA > 1.4 mg/ml
  • Age >50 years
  • Severity of LUTS


  1. Cornu et al. Impact of nocturia on the daily life of patients with lower urinary tract symptoms due to benign prostatic hyperplasia (Article in French). Prog Urol 2007; 17(5 Suppl 1): 1033-1036
  2. Emberton et al. Fortnightly review: Acute urinary retention in men: An age old problem. BMJ 1999; 318: 921-5
  3. Emberton et al. Managing the progression of lower urinary tract symptoms, benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int. 2007; 100: 249-253
  4. Speakman et al. Guideline for the primary care management of male lower urinary tract symptoms BJU Int. 2004: 93: (7) 985-990
  5. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
  6. Djavan et al. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004; 44:45-50

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Avodart and Combodart are registered trademarks of the GlaxoSmithKline group of companies.